Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Convertible Debt (2016 - 2020)

Historic Convertible Debt for Amicus Therapeutics (FOLD) over the last 5 years, with Q2 2020 value amounting to $2.2 million.

  • Amicus Therapeutics' Convertible Debt rose 642.51% to $2.2 million in Q2 2020 from the same period last year, while for Jun 2020 it was $2.2 million, marking a year-over-year increase of 642.51%. This contributed to the annual value of $2.1 million for FY2019, which is 9878.23% down from last year.
  • Per Amicus Therapeutics' latest filing, its Convertible Debt stood at $2.2 million for Q2 2020, which was up 642.51% from $2.2 million recorded in Q1 2020.
  • In the past 5 years, Amicus Therapeutics' Convertible Debt ranged from a high of $175.0 million in Q4 2018 and a low of $2.1 million during Q2 2019
  • Moreover, its 5-year median value for Convertible Debt was $156.9 million (2017), whereas its average is $100.8 million.
  • As far as peak fluctuations go, Amicus Therapeutics' Convertible Debt soared by 660.24% in 2018, and later plummeted by 9878.27% in 2019.
  • Amicus Therapeutics' Convertible Debt (Quarter) stood at $154.5 million in 2016, then grew by 6.28% to $164.2 million in 2017, then grew by 6.6% to $175.0 million in 2018, then crashed by 98.78% to $2.1 million in 2019, then grew by 3.38% to $2.2 million in 2020.
  • Its Convertible Debt stands at $2.2 million for Q2 2020, versus $2.2 million for Q1 2020 and $2.1 million for Q4 2019.